CLEAVE THERAPEUTICS
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
CLEAVE THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care
Founded:
2010-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.cleavetherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(415) 562-8117
Email Addresses:
[email protected]
Total Funding:
89.95 M USD
Technology used in webpage:
SPF SSL By Default Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail Google Maps Microsoft Azure DNS GoDaddy DNS GStatic Google Static Content
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Investors List
Astellas Venture Management
Astellas Venture Management investment in Series C - Cleave Therapeutics
Celgene
Celgene investment in Series C - Cleave Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series C - Cleave Therapeutics
OrbiMed
OrbiMed investment in Series C - Cleave Therapeutics
5AM Ventures
5AM Ventures investment in Series C - Cleave Therapeutics
U.S. Venture Partners
U.S. Venture Partners investment in Series C - Cleave Therapeutics
Arcus Ventures
Arcus Ventures investment in Series C - Cleave Therapeutics
OrbiMed
OrbiMed investment in Series B - Cleave Therapeutics
Astellas Venture Management
Astellas Venture Management investment in Series B - Cleave Therapeutics
Clarus Ventures
Clarus Ventures investment in Series B - Cleave Therapeutics
Official Site Inspections
http://www.cleavetherapeutics.com
- Host name: 85.119.180.107.host.secureserver.net
- IP address: 107.180.119.85
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Cleave Therapeutics" on Search Engine
Cleave Therapeutics, Inc. | LinkedIn
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways …See details»
Cleave Therapeutics Announces Acquisition of Clinical …
Jul 20, 2023 SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals …See details»
Cleave Therapeutics Company Profile 2024: Valuation, …
The company develops novel, small-molecule therapeutic inhibitors drugs that affect protein-degradation pathways upon which cancer cells depend for survival, enabling …See details»
Cleave Therapeutics: Taking a Risk on Oncology Drug …
Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful therapy was on track but faced an unclear future. …See details»
CASI Pharmaceuticals And Cleave Therapeutics Announce …
Jan 6, 2023 Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress pathways for …See details»
Cleave Therapeutics | VentureRadar
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP), also known as p97, as a novel target in protein homeostasis and cellular …See details»
Cleave Therapeutics Announces Preclinical Research …
Sep 9, 2020 Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress …See details»
Cleave Therapeutics Licenses First-in-Class VCP/P97 …
Mar 8, 2021 Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress …See details»
Cleave Therapeutics - Biocom CRO
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP), also known as p97, as a novel target in protein homeostasis and cellular …See details»
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
Jan 4, 2023 Overview. Included Materials. How can a successful executive assess her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy …See details»
CASI Press Release: Cleave Therapeutics Announces …
Jul 20, 2023 Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global …See details»
Eikon Acquires Broad Development Pipeline, Raises $106M in
Jun 1, 2023 The preclinical assets acquired from Cleave have potential use in both cancer and neurodegenerative diseases, according to the announcement. The $106 million is …See details»
Cleave Therapeutics - Org Chart, Teams, Culture & Jobs | The Org
Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis and cellular stress pathways …See details»
Cleave Therapeutics Announces Acquisition of Clinical and …
SAN FRANCISCO, July 20, 2023--Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: …See details»
Research programme: cancer therapeutics - Cleave Therapeutics
Cleave Therapeutics (formerly Cleave Biosciences) is developing small-molecule compounds as potential therapies for cancer. The drugs are targeting biologicalSee details»
Cleave Therapeutics' Leadership Team - Team members and org …
The leadership team at Cleave Therapeutics has a history of working in consulting, academia, and scientific research. They have experience with microscopy, studying …See details»
Cleave Therapeutics CEO, Founder, Key Executive Team, Board …
Dr. Laura Shawver is President, Chief Executive Officer and director of Silverback Therapeutics, a biopharmaceutical company advancing a pipeline of therapies that are …See details»
CB 5083 - AdisInsight - Springer
Cleave Therapeutics (formerly Cleave Biosciences) is developing CB 5083, a first-in-class small-molecule inhibitor of CDC48/p97 adenosine triphosphatase (p97.See details»
VCP (Cleave Therapeutics) - Drug Targets, Indications, Patents
Jan 25, 2024 VCP (Cleave Therapeutics), Initially developed by Cleave Therapeutics, Inc., Now, its global highest R&D status is Pending, Therapeutic Areas: Nervous System …See details»
Cleave Therapeutics - Yahoo Finance
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you …See details»